428 related articles for article (PubMed ID: 17975021)
21. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract][Full Text] [Related]
22. A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression.
Jin F; Fondell JD
Nucleic Acids Res; 2009 Aug; 37(14):4826-38. PubMed ID: 19520769
[TBL] [Abstract][Full Text] [Related]
23. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.
Yoon HG; Wong J
Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395
[TBL] [Abstract][Full Text] [Related]
24. Tumour necrosis factor alpha induces co-ordinated activation of rat GSH synthetic enzymes via nuclear factor kappaB and activator protein-1.
Yang H; Magilnick N; Ou X; Lu SC
Biochem J; 2005 Oct; 391(Pt 2):399-408. PubMed ID: 16011481
[TBL] [Abstract][Full Text] [Related]
25. Tissue transglutaminase expression promotes castration-resistant phenotype and transcriptional repression of androgen receptor.
Han AL; Kumar S; Fok JY; Tyagi AK; Mehta K
Eur J Cancer; 2014 Jun; 50(9):1685-96. PubMed ID: 24656569
[TBL] [Abstract][Full Text] [Related]
26. Expression of androgen receptor is negatively regulated by p53.
Alimirah F; Panchanathan R; Chen J; Zhang X; Ho SM; Choubey D
Neoplasia; 2007 Dec; 9(12):1152-9. PubMed ID: 18084622
[TBL] [Abstract][Full Text] [Related]
27. Inflammation-mediated abrogation of androgen signaling: an in vitro model of prostate cell inflammation.
Debelec-Butuner B; Alapinar C; Varisli L; Erbaykent-Tepedelen B; Hamid SM; Gonen-Korkmaz C; Korkmaz KS
Mol Carcinog; 2014 Feb; 53(2):85-97. PubMed ID: 22911881
[TBL] [Abstract][Full Text] [Related]
28. The androgen receptor induces integrin α6β1 to promote prostate tumor cell survival via NF-κB and Bcl-xL Independently of PI3K signaling.
Lamb LE; Zarif JC; Miranti CK
Cancer Res; 2011 Apr; 71(7):2739-49. PubMed ID: 21310825
[TBL] [Abstract][Full Text] [Related]
29. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.
Altuwaijri S; Lin HK; Chuang KH; Lin WJ; Yeh S; Hanchett LA; Rahman MM; Kang HY; Tsai MY; Zhang Y; Yang L; Chang C
Cancer Res; 2003 Nov; 63(21):7106-12. PubMed ID: 14612503
[TBL] [Abstract][Full Text] [Related]
30. Testosterone is a potential augmentor of antioxidant-induced apoptosis in human prostate cancer cells.
Gunawardena K; Murray DK; Meikle AW
Cancer Detect Prev; 2002; 26(2):105-13. PubMed ID: 12102144
[TBL] [Abstract][Full Text] [Related]
31. FUS/TLS is a co-activator of androgen receptor in prostate cancer cells.
Haile S; Lal A; Myung JK; Sadar MD
PLoS One; 2011; 6(9):e24197. PubMed ID: 21909421
[TBL] [Abstract][Full Text] [Related]
32. Diabetes protects from prostate cancer by downregulating androgen receptor: new insights from LNCaP cells and PAC120 mouse model.
Barbosa-Desongles A; Hernández C; De Torres I; Munell F; Poupon MF; Simó R; Selva DM
PLoS One; 2013; 8(9):e74179. PubMed ID: 24058525
[TBL] [Abstract][Full Text] [Related]
33. TRPM8 channel as a novel molecular target in androgen-regulated prostate cancer cells.
Asuthkar S; Velpula KK; Elustondo PA; Demirkhanyan L; Zakharian E
Oncotarget; 2015 Jul; 6(19):17221-36. PubMed ID: 25980497
[TBL] [Abstract][Full Text] [Related]
34. Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression.
Wang D; Montgomery RB; Schmidt LJ; Mostaghel EA; Huang H; Nelson PS; Tindall DJ
Cancer Res; 2009 Dec; 69(24):9448-56. PubMed ID: 19934328
[TBL] [Abstract][Full Text] [Related]
35. Thymoquinone attenuates proinflammatory responses in lipopolysaccharide-activated mast cells by modulating NF-kappaB nuclear transactivation.
El Gazzar MA; El Mezayen R; Nicolls MR; Dreskin SC
Biochim Biophys Acta; 2007 Apr; 1770(4):556-64. PubMed ID: 17292554
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of NF-kB decoy oligodeoxynucleotides in a prostate cancer cell line.
Fang Y; Sun H; Zhai J; Zhang Y; Yi S; Hao G; Wang T
Asian Pac J Cancer Prev; 2011; 12(10):2721-6. PubMed ID: 22320981
[TBL] [Abstract][Full Text] [Related]
37. Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells.
Lin HP; Lin CY; Hsiao PH; Wang HD; Jiang SS; Hsu JM; Jim WT; Chen M; Kung HJ; Chuu CP
PLoS One; 2013; 8(12):e82625. PubMed ID: 24349321
[TBL] [Abstract][Full Text] [Related]
38. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells.
Gasparian AV; Yao YJ; Kowalczyk D; Lyakh LA; Karseladze A; Slaga TJ; Budunova IV
J Cell Sci; 2002 Jan; 115(Pt 1):141-51. PubMed ID: 11801732
[TBL] [Abstract][Full Text] [Related]
39. Androgen Receptor Upregulates Mucosa-Associated Lymphoid Tissue 1 to Induce NF-κB Activity via Androgen-Dependent and -Independent Pathways in Prostate Carcinoma Cells.
Chang KS; Chen ST; Sung HC; Hsu SY; Lin WY; Hou CP; Lin YH; Feng TH; Tsui KH; Juang HH
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047218
[TBL] [Abstract][Full Text] [Related]
40. Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells.
Bhattacharyya RS; Krishnan AV; Swami S; Feldman D
Mol Cancer Ther; 2006 Jun; 5(6):1539-49. PubMed ID: 16818513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
